IM Cannabis (IMCC) Income towards Parent Company (2020 - 2026)
IM Cannabis' (IMCC) quarterly Income towards Parent Company came in at -$1.8 million in Q1 2026, down 1575.03% year-on-year from $121960.4 in Q1 2025, and up 67.14% quarter-over-quarter from -$5.5 million in Q4 2025.
IM Cannabis (IMCC) Income towards Parent Company (2020 - 2026) Analysis & Trends
IM Cannabis' Income towards Parent Company history runs 7 years deep, the most recent figure standing at -$1.8 million for Q1 2026.
- On a quarterly basis, Income towards Parent Company fell 1575.03% year-over-year to -$1.8 million in Q1 2026; TTM through Mar 2026 was -$5.8 million, a 69.75% increase from a year earlier, with the FY2025 full-year figure at -$8.1 million, down 4.99% from the prior year.
- Income towards Parent Company advanced to -$1.8 million in Q1 2026 per IMCC's latest filing, from -$5.5 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $2.9 million in Q1 2022 and bottomed at -$94.8 million in Q3 2022.
- The 5-year median for Income towards Parent Company is -$1.2 million (2025), against an average of -$8.8 million.
- Across the five-year window, Income towards Parent Company tumbled 2124020250.79% in 2024 and jumped 492.52% in 2025, its largest moves.
- Year by year, Income towards Parent Company stood at -$17.5 million in 2022, then advanced by 29.04% to -$12.4 million in 2023, then declined by 16.0% to -$14.4 million in 2024, then surged by 62.07% to -$5.5 million in 2025, then soared by 67.14% to -$1.8 million in 2026.
- Per Business Quant, the three latest IMCC Income towards Parent Company figures stand at -$1.8 million (Q1 2026), -$5.5 million (Q4 2025), and $2.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | IM Cannabis | 517,043.18 | -215,079.33 | 1.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.80 Mn |
| Dec 31, 2025 | -5.47 Mn |
| Sep 30, 2025 | 2.65 Mn |
| Jun 30, 2025 | -1.16 Mn |
| Mar 31, 2025 | 121,960.38 |
| Dec 31, 2024 | -14.43 Mn |
| Sep 30, 2024 | -675,875.24 |
| Jun 30, 2024 | -4.11 Mn |
| Mar 31, 2024 | -4.47 Mn |
| Dec 31, 2023 | -12.44 Mn |
| Sep 30, 2023 | 1.59 Mn |
| Jun 30, 2023 | 0.19 |
| Mar 31, 2023 | -664,247.34 |
| Dec 31, 2022 | -17.53 Mn |
| Sep 30, 2022 | -94.80 Mn |
| Jun 30, 2022 | -2.45 |
| Mar 31, 2022 | 2.89 Mn |
| Dec 31, 2021 | -3.27 Mn |
| Sep 30, 2021 | -5.15 Mn |
| Jun 30, 2021 | -3.77 Mn |